Teleflex (TFX) recently launched its new Pressure Injectable Arrowg+ard Blue Plus MSB Procedure Kit in Europe, the Middle East and Africa (EMEA). This is regarded as a significant addition to the company’s market-leading portfolio of Centrally-Inserted Central Catheters.The Kit also features the Arrowg+ard Blue Plus CVC (central venous catheter), the only full-spectrum antimicrobial CVC that protects against gram-positive and gram-negative bacteria and fungi — the key infectious pathogens responsible for CL ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

WAYNE, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 36th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Tuesday, December 3, 2024, at 9:30 a.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is ...

Company Overview - Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to become the most trusted partner in healthcare through purpose-driven innovation and world-class products [2] - Teleflex offers a diverse portfolio of solutions across multiple therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] Brand Portfolio - Teleflex owns several trusted medical brands including Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™ [3] - These brands are united by a common sense of purpose to empower the future of healthcare [3] Leadership Engagement - Liam Kelly, Chairman, President and CEO of Teleflex, is scheduled to speak at the Jefferies London Healthcare Conference on November 21, 2024 at 9:30 a.m. GMT [1] - A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website [1]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Teleflex Incorporated (TFX) posted third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of $3.49, down 3.1% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 3.3%.GAAP EPS came in at $2.36 in the third quarter, down 32.4% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the announcement, shares of the company tumbled 14.5% yesterday, finishing the session at $201.06.TFX’s Q3 RevenuesNet revenues in ...

Financial Data and Key Metrics Changes - Teleflex reported revenues of $764.4 million for Q3 2024, representing a 2.4% year-over-year increase on a GAAP basis and a 2.2% increase on an adjusted constant currency basis, slightly below the guidance of $765 million to $770 million due to unexpected softness in the OEM business [6][7] - Adjusted earnings per share for Q3 was $3.49, a decrease of 4.1% year-over-year, but higher than expectations due to strong margin performance [7][29] - Adjusted gross margin was 60.8%, a 140 basis point increase year-over-year, primarily driven by the termination of the MSA and the acquisition of Palette, despite manufacturing inefficiencies and cost inflation [26] - Adjusted operating margin was 27.3%, reflecting a 10 basis point year-over-year increase [27] Business Line Data and Key Metrics Changes - Vascular Access revenue increased 6.3% year-over-year to $180.9 million, driven by strong performance in peripheral and central access products [11] - Interventional revenue rose 11.4% year-over-year to $149.9 million, with expectations for increased contributions from intra-aortic balloon pump revenues in Q4 [12] - Anesthesia revenue grew 3.4% year-over-year to $101.1 million, led by intraosseous and hemostatic products [12] - Surgical revenue decreased 1% year-over-year to $111.7 million, with solid underlying trends offset by tough comparisons in the ligation portfolio [13] - Interventional Urology revenue increased 13.3% year-over-year to $83.4 million, driven by Barrigel revenue following the acquisition of Palette Life Sciences [14] - OEM revenue increased 0.1% year-over-year to $82.6 million, softer than expected due to a large customer’s decision to vertically integrate a component [14] Market Data and Key Metrics Changes - Americas revenues were $433.3 million, a 1.5% increase year-over-year, impacted by prior year MSA revenues [8] - EMEA revenues increased 3.9% year-over-year to $150.2 million, driven by improved product availability and utilization [8] - Asia revenues were $98.3 million, a 5% increase year-over-year, affected by ongoing doctor strikes in South Korea [9] Company Strategy and Development Direction - The company is focused on driving durable growth through its diversified portfolio and global footprint, with an emphasis on execution and margin expansion [41] - Teleflex is actively pursuing inorganic growth opportunities, including M&A, while maintaining a disciplined capital allocation strategy [41][52] - The integration of Palette Life Sciences is nearly complete, with expectations for continued strong performance from Barrigel and UroLift [80] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with OEM performance but noted strong margin expansion and free cash flow, positioning the company well for capital allocation [47] - The company anticipates continued headwinds in UroLift and OEM, with expectations for stabilization in 2025 [57] - Management remains optimistic about the intra-aortic balloon pump market, expecting significant share gains in the U.S. due to competitor challenges [19][21] Other Important Information - Cash flow from operations for the year-to-date was $435.6 million, up from $372.4 million in the prior year [30] - The company has a cash balance of $277.8 million at the end of Q3, with net leverage at approximately 1.7x [31] - Teleflex raised its 2024 revenue guidance for Palette to $73 million to $75 million, reflecting strong performance [18] Q&A Session Summary Question: What is the impact of OEM on the top line? - Management clarified that the OEM business was the larger impact on guidance, primarily due to vertical integration and inventory management issues, totaling approximately $14 million for the year [48] Question: How does the company view the balance between share repurchase and M&A? - Management indicated that the balance sheet is strong, allowing for both share repurchase and M&A opportunities, with a focus on non-EPS dilutive assets [50][52] Question: What is the outlook for UroLift and OEM in 2025? - Management noted that the OEM headwind will continue into the first half of next year, while UroLift remains challenged primarily in the office side of service [55][57] Question: What is the expected contribution from intra-aortic balloon pumps in Q4? - Management expects over $10 million in orders for intra-aortic balloon pumps in Q4, driven by both normal replacement cycles and conversions from competitors [68][94] Question: How is the integration of Palette Life Sciences progressing? - The integration is nearly complete, with strong performance from Barrigel and expectations for continued growth [80]

For the quarter ended September 2024, Teleflex (TFX) reported revenue of $764.38 million, up 2.4% over the same period last year. EPS came in at $3.49, compared to $3.64 in the year-ago quarter.The reported revenue represents a surprise of -0.43% over the Zacks Consensus Estimate of $767.64 million. With the consensus EPS estimate being $3.38, the EPS surprise was +3.25%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Teleflex (TFX) came out with quarterly earnings of $3.49 per share, beating the Zacks Consensus Estimate of $3.38 per share. This compares to earnings of $3.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.25%. A quarter ago, it was expected that this medical equipment maker would post earnings of $3.33 per share when it actually produced earnings of $3.42, delivering a surprise of 2.70%.Over the last four quarters, the co ...